Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Several other institutional investors and hedge funds also recently made changes to their positions in AVXL. Orion Capital Management LLC purchased a new stake in shares of Anavex Life Sciences in the third quarter valued at about $59,000. Dark Forest Capital Management LP purchased a new stake in shares of Anavex Life Sciences in the third quarter valued at about $76,000. Blair William & Co. IL bought a new position in Anavex Life Sciences during the third quarter valued at about $80,000. China Universal Asset Management Co. Ltd. grew its position in Anavex Life Sciences by 351.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,498 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 7,395 shares during the period. Finally, Premier Path Wealth Partners LLC bought a new position in Anavex Life Sciences during the fourth quarter valued at about $116,000. Hedge funds and other institutional investors own 31.55% of the company’s stock.
Wall Street Analyst Weigh In
Separately, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a research report on Friday, May 10th.
Victory Capital Management Inc. Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)
(From Trainguy1 on ST)
https://www.defenseworld.net/2024/05/29/victory-capital-management-inc-takes-position-in-anavex-life-sciences-corp-nasdaqavxl.html
BNP Paribas Financial Markets Raises Stock Holdings in Anavex Life Sciences Corp. (NASDAQ:AVXL)
Posted by Defense World Staff on May 29th, 2024
(From Trainguy1 at ST)
https://www.defenseworld.net/2024/05/29/bnp-paribas-financial-markets-raises-stock-holdings-in-anavex-life-sciences-corp-nasdaqavxl.html
Every day this week was a green gain of the previous day. A solid green week, it has been quite a while since AVXL pulled that hat trick.
From ST: Veliger
$AVXL State Street doubled their stake to 7.3M shares, surpassing BlackRock (6.7M) as the largest owner. We also saw the largest short side players (DLD & Goldman) close their large put bets in the past week. The tide may be turning.
I also liked that Goldman closed out their puts then rolled the money into long shares. These guys made a killing.
Thanks Falcon for posting the link I overlooked.
Mayo just posted his analysis of the CC on ST:
-----------------------------------------------------------------------------------------
Brief Summary of the 9 May 2024 CC:
sotcanalytics.com/update-co...
Apologies for lateness. Thanks for reading, exciting times ahead.
Bullish
-------------------------------------------------------------------------------------------
I have not posted for a while due to recent surgery and rehab, and I'm recovering well.
From ST. Borrowing rates for shorts has increased dramatically; it could make some shorts cover on that fact alone.
ConfirmationBiasSuxs
9:35 AM
$AVXL 9.4% for the borrow rate... that's an 1100% increase in 60 days... Something is happening
coinspitter
9:39 AM
@ConfirmationBiasSuxs I see 7.1% at IB but agree, its getting expensive for the big shortie
@ConfirmationBiasSuxs Fintel is listing 9.40% right now
It is cyclical; but still highly priced on the desirables.
John k9uwa, consider taking some of you AVXL profits once the stock is evaluated on Alzheimer, Rett, and Parkinson WW sales and get back into muscle cars. Besides the fun times they are a great investment too. I bought mine in 1990 for $9K, and is a six figure car now, the 1970 454 Chevelle Convertible SS are extremely rare and at factory 450HP and 500 TQ was the highest HP Muscle car ever made back in those days (Mine is modified and well over 500 HP). Life is too short to not enjoy it when you can. The local car shows and meets are good times and you meet new friends. Fun fact, a 1970 454 Chevelle Convertible SS like mine was undefeated in 1970 and 1971, nicknamed the Hemi Killer, by beating all the Hemis and big block Fords it came up against, it sold for over a Million $$ at auction decades ago.
After Hour single big trade..... 17:12:25 -- $6.60 -- vol- 45,979 That after hour late SP and Vol also supports the +9.09% gain and closing SP of $6.60 near the HOD of $6.62 minutes before the close. Bullish for tomorrow.
https://www.nasdaq.com/market-activity/stocks/avxl/after-hours-trades
Over on the other board there are many calling for Missling to release the AD data in a PR before the forth coming science/medical paper that will be published in a major journal. FWIW, this is my reply and opinion in case it is debated here:
"In corporate finance, Contingent Value Rights (CVR) are rights granted by an acquirer to a company’s shareholders, facilitating the transaction where some uncertainty is inherent. CVRs may be separately tradeable securities; they are occasionally acquired by specialized hedge funds."
https://en.wikipedia.org/wiki/Contingent_value_rights
From ST, this is good news for longs looking for a possible short squeeze:
$AVXL Short borrow rate just jumped again 3.76%!!... higher it goes the more pressure on the shorts to clear... and that's millions of shares they need to buy back!
Bullish"
(ConfirmationBiasSuxs at ST)
EMA may be leading the way for an Anavex into European Alzheimer market as the SOC. I think they most certainly will be well received considering the outstanding safety record combined with superior efficacy and positive RWD. EMA covers 7 Million AD patients and rising fast; the cost is crushing their budgets into the red, It is a top subject in the cost of health and financial problems. They will not only see this from a compassionate view; but saving Billions in the future as the population ages. I think they will push it through as fast as allowed. Obviously the market is not as enthused as most of us shareholders. However I like to think ahead like we do in chess; sometimes you have to pull back to see where trends are going. I think months from now, not years, that Alzheimer with Anavex safe pill treatments will be two topics that will start heating up.
A short time for waiters, a scary time for shorts.
A market of 7 Million Alzheimer patients foretells SOC revenues in the high multi Billions.
Best part is saving the minds of the elderly and live in dignity,
MayoMobile on ST:
Anavex: -12.93 on RSBQ
DAYBUE: -4.9 on RSBQ
Anavex end score was so much better.
$9.84 HOD just printed.
Has a decent shot of MM Vol close
I think TGA will be the be making Anavex news soon likely in the next quarter.
Thalidomide was used on my second wife who had a very rare cancer. It stopped the blood supply to the tumors for 2 years, resulting in stopping the tumors growth, but it did not eliminate the cancer, The Doc tried her on a different promising medication that did not work and she eventually died after a 5 year fight. So in some cases Thalidomide is effective, it gave her an extra two years of life which was a blessing.
My first wife also died of cancer, she fought it for 4 years.
Two weeks ago my present wife has been diagnosed with CLL Leukemia. Fortunately it is a slow growth.
Merry Christmas my friends, hold your love ones close.
I
Market turned sharply red around mid day. Dow, Nasdaq, S&P, Russell, and XBI as well as AVXL in the red. Nothing to do but ride it out or buy shares cheaper. I'm looking at the call options too.
MayoMobile ...(From ST).
7:43 AM
$AVXL Powerful science in this morning’s Rett PR.
This is the first genomic breakout in the Anavex Rett Suite and shows congruence with prior genomic breakouts in AD and PDD patients.
Specifically, strong response in mitochondrial protein expression along with other metabolic & transcription/translation expression. This is complemented by additional neurodevelopmental focused gene improvements. In my opinion, this allows prior AD/PDD genomic data to be coupled in with Rett NDA.
Additionally, the heat map is wonderful for the layperson and clearly identifies probably 7 super responders (of 18 dosed patients) with only 1-2 ‘non’ responders. There is a clear delineation between dosed and placebo patients and bodes very well for primary outcomes in the large forthcoming RS-003 trial data.
Looking forward to analyzing this more later.
Looks like stop losses were taken out during first few minutes. MM needed shares.
If that can be verified, that would be a $6,461,368 trade.
If so, that is a pretty big bite out of the total of shares shorted.
Needs verification.
AVXL. Population-Based Characterization of the Pharmacokinetics and Food Effect of ANAVEX3-71, a Novel Sigma-1 Receptor and Allosteric M1 Muscarinic Receptor Agonist in Development for Treatment of Frontotemporal Dementia, Schizophrenia, and Alzheimer Disease.
https://pubmed.ncbi.nlm.nih.gov/38073274/
FWIW Early in After hours a decent size single trade:
16:02:02 $8.01 Vol - 33,931
AVXL on lower volume pretty much followed the XBI today.
It's good to see the oversold XBI rising above the red markets today, even if it is a little gain: 79.54 +0.74 (+0.94%)
I have seen a couple of articles talk about the Bios as well as the XBI being long term oversold and was due to recover. The Bio pendulum moving from oversold to buying. ..
"Shares of XBI Now Oversold"
October 12, 2023
"Looking at a chart of one year performance XBI's low point in its 52 week range is $68.48 per share, with $92.60 as the 52 week high point"
https://www.nasdaq.com/articles/shares-of-xbi-now-oversold-0
The higher the price and the lower the cost, the higher the Profit Margin. In any case, your Profit Margin can never exceed 100 percent, which only happens if you're able to sell something that cost you nothing.
https://personalmba.com/profit-margin/#:~:text=((Revenue%20%2D%20Cost)%20%2F%20Revenue,)%20*%20100%20%3D%20%25%20Profit%20Margin&text=The%20higher%20the%20price%20and,something%20that%20cost%20you%20nothing.
Due Diligence for those seeking new knowledge, multiple sources:
Multiple Clinical Milestones Achieved and Promising Ongoing Development Driving Progress towards Commercialization
See page 15; for viewing the extensive pipeline and multiple drugs for various diseases.
This was the last Anavex Corporate Presentation May 2023; there has been progress since May this year.
https://www.anavex.com/_files/ugd/79bcf7_97da6311c3b643bea8e9a6659bb51422.pdf
-----------------------------------------------------------------------------------------------------------------------------------
How Soon Might Anavex's Alzheimer's Drug Be Approved? The Good/Bad News
Nov. 29, 2023 7:21 AM ET Anavex Life Sciences Corp. (AVXL)
Snip:
Summary:
"The EU recommends Anavex proceed with a full approval application for Alzheimer's drug Blarcamesine based on full Phase 2b/3 trial data.
The U.S. FDA may grant accelerated approval to Anavex's Blarcamesine based on biomarker data alone. Blarcamesine is far safer than Biogen's Leqembi, which was granted accelerated approval in three months.
The FDA may accept Anavex's ongoing ATTENTION-AD study as a supplement to the Phase 2b/3 trial, potentially shortening the full and regular approval timeline. That data comes out in 2023.
human brain"
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173316790
------------------------------------------------------------------------------------------------------------------------------
SOTC Analytics strives to report medical intelligence pertaining to neurodegenerative & neurodevelopmental disorders to include Alzheimer's Disease, Parkinson's Disease, Rett Syndrome, Angelman Syndrome, Fragile X, and more:
https://www.sotcanalytics.com/
---------------------------------------------------------------------------------------------------------------------------------
Update Compendium 2023
https://www.sotcanalytics.com/update-compendium-2023
Does Fidelity offer LV-2 ?
I took advantage of the drop in SP on the Rett delay and wired funds in for decent size cheap buys.
Nothing has changed with the company to account for the drop in SP other than the Rett delay; a very temporary problem that does not change the investment.
FWIW The funds showed up in my Schwab account by the time I got home from the bank; TDA was never that quick.
Thanks Kdskds, I'm in.
What is the meeting pass code? Thanks
In a way, the shorts have done longs a favor by crushing the SP so we longs can load up on cheap shares by creating a much larger position than what would not have been possible without all those cheap short sells intended to keep the SP deflated.
However the shorts have literally painted themselves into the proverbial corner. They will not be able to keep a lid on the coming good news PRs that will indicate significant future AD and Rett revenues that will force the SP higher as the powerful Institutes add to their position, along with retail which will be buying up what shares become available; causing a squeeze that will be forcing the shorts to cover with buying shares and also buying call options. Who would be selling? That is the short's unsolvable dilemma.